相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer
Dan Lu et al.
CLINICAL PHARMACOKINETICS (2013)
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
Luis Fayad et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine
Randall Dere et al.
BIOANALYSIS (2013)
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Manish Gupta et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
Muralidhar Beeram et al.
CANCER (2012)
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A Guide to Rational Dosing of Monoclonal Antibodies
Shuang Bai et al.
CLINICAL PHARMACOKINETICS (2012)
Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
Ben-Quan Shen et al.
CURRENT DRUG METABOLISM (2012)
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
Simona Lapusan et al.
INVESTIGATIONAL NEW DRUGS (2012)
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
Manish Gupta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Mark Barok et al.
CANCER LETTERS (2011)
Population Pharmacokinetic Evaluation with External Validation and Bayesian Estimator of Voriconazole in Liver Transplant Recipients
Kelong Han et al.
CLINICAL PHARMACOKINETICS (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology
Saileta Prabhu et al.
THERAPEUTIC DELIVERY (2011)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Assessment of the validity of a population pharmacokinetic model for epirubicin
Lorraine D. Ralph et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
JA Dowell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)